Palbocent 125 mg contains palbociclib, a prescription cancer medicine manufactured by Incepta Pharmaceuticals Ltd. It belongs to a targeted treatment group called cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palbocent is used as part of combination treatment for certain adults with hormone receptor-positive (HR-positive), HER2-negative advanced or metastatic breast cancer. Depending on the treatment plan, palbociclib may be combined with an aromatase inhibitor or fulvestrant. Because Palbocent affects cell growth and blood-cell production, treatment should be prescribed and monitored by an oncology specialist. It is not a medicine for self-treatment.

What Is Palbocent 125 mg?

Palbocent 125 mg is an oral formulation of palbociclib. Palbociclib works by blocking CDK4 and CDK6, proteins involved in controlling the cell cycle. Blocking these proteins can slow the transition of cancer cells from the G1 phase into the S phase. This can reduce the ability of certain cancer cells to continue dividing. Palbocent is generally not used alone for the approved breast cancer indications described above. It is prescribed with endocrine treatment selected by the treating oncologist.

What Is Palbocent 125 mg Used For?

Palbocent is used for certain adults with HR-positive, HER2-negative advanced or metastatic breast cancer.

It may be prescribed:

• With an aromatase inhibitor as endocrine-based treatment.
• With fulvestrant after disease progression following endocrine therapy.
• With appropriate endocrine therapy and ovarian suppression when clinically indicated in premenopausal or perimenopausal women.

Your oncologist will determine whether palbociclib is appropriate based on your cancer type, receptor status, previous treatment, medical history, and other medicines.

How Does Palbociclib Work?

Palbociclib is a selective CDK4/6 inhibitor. CDK4 and CDK6 help regulate cell-cycle progression. These proteins can contribute to the movement of cells from the G1 phase toward DNA synthesis and cell division. Palbociclib inhibits CDK4 and CDK6 activity. This can produce cell-cycle arrest and reduce the proliferation of susceptible cancer cells. The treatment is commonly combined with endocrine therapy. The two treatments act through different but complementary pathways involved in hormone-driven breast cancer.

How to Take Palbocent 125 mg

The usual starting dose of palbociclib is 125 mg once daily.

The standard schedule is:

• Days 1–21: Take one 125 mg dose once daily.
• Days 22–28: Take no palbociclib.
• Day 29: Begin the next treatment cycle.

This creates a 28-day treatment cycle. The prescribing information recommends taking palbociclib with food. Take Palbocent exactly as prescribed. Do not change the dose or treatment schedule without your oncology team.

What If You Miss a Dose?

If you miss a dose, do not take an extra dose to replace it unless your doctor specifically instructs you to do so. Contact your healthcare professional or pharmacist if you are unsure what to do after a missed dose. If vomiting occurs after taking a dose, do not automatically repeat the dose. Follow the instructions provided by your oncology team.

Dose Adjustments

Not every patient remains on the initial 125 mg dose. Your oncologist may interrupt treatment or reduce the dose if blood counts fall too low or significant adverse reactions develop. Approved palbociclib dosage levels include 125 mg, 100 mg, and 75 mg. Dose changes should be based on laboratory results, symptoms, treatment response, and overall tolerability.

Never reduce, increase, or restart Palbocent on your own.

Blood Tests and Monitoring

Palbociclib can reduce neutrophil and other blood-cell counts. Regular blood testing is therefore an important part of treatment. The prescribing information recommends a complete blood count before treatment, at the beginning of each cycle, and on Day 15 of the first two cycles, with additional testing when clinically appropriate. Your doctor may also monitor liver function and assess symptoms that could indicate other treatment-related complications.

Palbocent 125 mg Side Effects

Like other cancer medicines, palbociclib can cause side effects. Their severity varies between patients.

Commonly reported adverse reactions include:

• Neutropenia
• Leukopenia
• Infections
• Fatigue
• Nausea
• Anemia
• Stomatitis
• Diarrhea
• Vomiting
• Thrombocytopenia
• Hair loss or thinning
• Rash
• Reduced appetite
• Fever

Clinical data show that neutropenia is particularly common with palbociclib treatment. The occurrence of a side effect does not mean every patient will experience it. Tell your healthcare team about new, persistent, or worsening symptoms.

Serious Side Effects Requiring Medical Attention

Some reactions require urgent medical assessment.

Contact your healthcare team promptly if you develop:

• Fever or signs of infection
• Severe weakness or unusual bleeding
• New or worsening cough
• Difficulty breathing
• Chest discomfort
• Symptoms suggesting significant liver problems

Palbociclib has an important warning for neutropenia. Interstitial lung disease and pneumonitis have also been reported and can be serious. A fever during treatment should not be ignored, especially when your white blood cell count is low.

Palbocent 125 mg Drug Interactions

Palbociclib is metabolized mainly through the CYP3A pathway. Medicines that strongly inhibit or induce CYP3A can change palbociclib exposure.

Your doctor should know about all medicines you take, including:

• Prescription medicines
• Over-the-counter products
• Vitamins
• Herbal supplements
• Traditional medicines

Strong CYP3A inhibitors should generally be avoided when possible. Strong CYP3A inducers should also be avoided because they can reduce palbociclib exposure. Do not start a new medicine or supplement without checking with your doctor or pharmacist.

Food and Lifestyle Considerations

Follow the food instructions given with your prescription. Because palbociclib can interact with substances that affect CYP3A, discuss grapefruit, grapefruit juice, and other foods or supplements with your pharmacist or oncology team before consuming them regularly. During treatment, practical measures such as good hygiene and avoiding close contact with people who have contagious infections may be helpful when your immune-cell counts are low.

Pregnancy and Breastfeeding

Palbociclib can cause fetal harm. People who can become pregnant should discuss effective contraception with their healthcare professional before and during treatment. The appropriate duration after treatment should follow the current prescribing information and medical advice. Breastfeeding is not recommended during palbociclib treatment. The manufacturer information advises avoiding breastfeeding during treatment and for a period after the final dose. If pregnancy occurs during treatment, contact your healthcare professional promptly.

Who Should Not Use Palbocent Without Medical Advice?

Palbocent is a prescription oncology medicine and should only be used when prescribed by an appropriately qualified healthcare professional.

Tell your doctor if you have:

• Previous severe reactions to palbociclib
• Liver problems
• Kidney problems
• Current or recurrent infections
• Low blood-cell counts
• Pregnancy or plans for pregnancy
• Breastfeeding
• Other cancer treatments
• Any medicines or supplements you currently use

Your oncology team will determine whether the expected benefits outweigh the potential risks.

Storage of Palbocent 125 mg

Store Palbocent according to the manufacturer’s package instructions. Keep the medicine in its original packaging and protect it from unsuitable temperatures, moisture, and conditions that could affect product quality. Keep medicines away from children and pets. Always check the product packaging for specific storage instructions before use.

Why Choose Palbocent 125 mg?

Palbocent provides a palbociclib treatment option manufactured by Incepta Pharmaceuticals Ltd.

Important product information includes:

• 125 mg palbociclib strength
• Oral capsule formulation
• CDK4/6 targeted mechanism
• Established 21-day-on and 7-day-off treatment schedule
• Use alongside appropriate endocrine therapy
• Prescription-based oncology treatment
• Global access and sourcing support through Selxen

Incepta’s official product information identifies Palbocent as a palbociclib product and lists its 125 mg capsule presentation.

Palbocent 125 mg and Treatment Expectations

Palbociclib is intended to help control certain advanced or metastatic breast cancers rather than being presented as a guaranteed cure. Treatment duration varies between patients. Your oncologist may continue treatment while the cancer remains controlled and the medicine remains tolerable. Regular appointments and laboratory monitoring are essential. Treatment may be interrupted, adjusted, or discontinued when medically necessary.

Ordering Palbocent 125 mg Through Selxen

Palbocent 125 mg is a prescription medicine. Patients should have a valid prescription and use a legitimate pharmaceutical sourcing channel. Through Selxen, patients and healthcare providers can receive global access and product-sourcing support for Palbocent 125 mg, subject to applicable prescription, importation, shipping, and regulatory requirements in the destination country.

Before placing an order, verify:

1. The prescribed medicine and strength.
2. The quantity required by your physician.
3. Product packaging and expiry information.
4. Prescription requirements in your country.
5. Shipping and import requirements.
6. Storage and handling conditions during delivery.

Availability, pricing, and delivery options can vary by country.

Frequently Asked Questions

Is Palbocent 125 mg a chemotherapy medicine?

Palbocent contains palbociclib, a targeted CDK4/6 inhibitor. It is different from traditional cytotoxic chemotherapy. It is commonly combined with endocrine therapy for appropriate breast cancer patients.

What is the generic name of Palbocent?

The generic name is palbociclib.

Who manufactures Palbocent 125 mg?

Palbocent 125 mg is manufactured by Incepta Pharmaceuticals Ltd. The manufacturer’s product page lists each capsule as containing palbociclib 125 mg.

Can I take Palbocent without a prescription?

No. Palbocent is a prescription oncology medicine. It should be used only under the supervision of a qualified healthcare professional.

Can Palbocent be taken alone?

Palbociclib is generally prescribed with appropriate endocrine therapy for the breast cancer indications described in product and regulatory information. Your oncologist chooses the combination based on your clinical situation.

How long do I take Palbocent 125 mg?

Treatment length is individualized. The standard cycle is 21 days of treatment followed by 7 days without palbociclib. Treatment may continue while the medicine is beneficial and tolerable.

What is the most important side effect to watch for?

A major concern is neutropenia, which can increase infection risk. Regular blood-count monitoring is therefore essential.

Can Palbocent 125 mg cure breast cancer?

Palbociclib should not be marketed as a guaranteed cure. In appropriate patients, it is used to help control advanced or metastatic breast cancer and delay disease progression as part of combination treatment.

Is Palbocent available internationally?

Selxen provides global access and sourcing support, subject to local prescription and pharmaceutical regulations. Availability can vary by destination.

Important Medical Disclaimer

This product information is provided for educational purposes and does not replace advice from an oncologist, physician, or pharmacist. Palbocent 125 mg is a prescription medicine and should not be started, stopped, or dose-adjusted without medical supervision. Product indications, approved uses, dosage instructions, and regulatory requirements can differ between countries. Always follow the prescribing information supplied with your medicine and the instructions of your treating healthcare professional.